Surviving clones were subject to next-generation sequencing (NGS) to identify which genes, following their ablation, allowed the aberrant ALK-expressing NB cells to survive in the presence of an ALK inhibitor, therefore representing potential therapeutic targets. Here, ALK is linked to neuroblastoma.